inextricably intertwined. Patients have a right to expect the best treatment, and professional carers have a corresponding duty to know what the best treatments are. Anecdote and opinion can only be short-term expedients; reliable knowledge derived from methodologically sound surveys and studies must be the goal. For example, clinical trials in the 1970s showed that, contrary to popular opinion, as an analgesic diamorphine is no better than morphine,' and the Brompton Cocktail has no advantage over a simple solution of morphine.2,3 Similarly, in the 1980s it was shown that slow-release morphine tablets every 12 hours are as effective as ordinary preparations of morphine administered every four hours.4
Likewise, the benefits and limitations of corticosteroids in palliative care have been clarified 5 It is encouraging, therefore, that the volume of research is growing. A survey on palliative care in Europe showed that in 1990 over 100 centres were undertaking research.6 Over 60 of these are in the UK. individual projects.8 Cancer Relief Macmillan Fund (CRMF) has supported research both directly and indirectly. Two important projects were the survey into stress in nurses caring for cancer patients and a MORI survey on the needs of people with cancer (reports available from CRMF). By its sponsorship of academic medical and nursing posts and by pump-priming many of the senior registrar posts in palliative medicine, CRMF has stimulated a wide range of ongoing research activity. Help the Hospices has also sponsored research projects. As yet, however, there is no 'clearing-house' in the UK for processing grant applications for palliative care research projects.
Hitherto, most research has concentrated either on symptom relief or psychological distress and organizational aspects.9-14 There is a need, however, for rigorous investigation by multiprofessional research teams of death as a social and a spiritual event, as experienced by dying persons and those who care for them. In such areas, the dynamic and complex nature of dying makes measuring and counting a much more difficult task and requires robust methods to examine and expose that complexity. 15, 16 After all, just what is the value of a hug?17 Using a modified Spitzer Quality of Life Index, a young dying man scored 2/10 on a day when he said that the last year had been the best of his life. 16 Similarly, a 38-year-old paraplegic man with congenital neurofibromatosis stated four days before he died that his quality of life was 9.5 on a scale of 0-10.
Methodology is also a problem in relation to pain and symptom control. There are still no standard definitions and grades,18 which makes results difficult to interpret and comparisons between centres impossible. Furthermore, a reluctance to 'bother' the patient leads to reliance on the reports of relatives or staff with an inevitable resultant bias. Yet, as has been said, ' we should not discriminate against patients with a terminal illness by not listening to their views'.19
The current interest in audit must not allow this to become a 'soft' substitute for research.
Audit is about doing the right thing and doing it better; research is asking what the right thing iS.20 Research begins by collating and examining clinical experience or attitudes (retrospective survey, structured questionnaire) and, ideally, comparing the results with similar data from other centres. There is then likely to be a move to prospective surveys and observational studies. Furthermore, particularly in relation to pain and symptom management, there will be times when a formal randomized controlled trial will be indicated. The latter, however, are notoriously difficult to conduct in the average palliative care unit because of the scarcity of physically stable patients who fulfil the entry criteria. There is also a need to keep the roles of clinician and researcher separate. Logic points, therefore, to multicentre studies with paid part-time research assistants co-ordinated by a full-time clinical projects manager.
In the absence of support from a cancer charity, most studies have been financed by drug companies, small local research grants, private donations and the diversion of funds from patient care. Such an ad hoc approach is not satisfactory in the long-term. It prevents adequate forward planning and is wasteful in terms of man-hours spent in raising relatively small sums. It is encouraging that the report of the EC Subcommittee on Palliative Cancer Care, as yet unpublished, stresses the need for research as well as education and training, and urges that funding should be made available. The 1990 WHO report on cancer pain relief and palliative care contained the same message. 21 But where is the extra money going to come from? Will it be new money? This is unlikely in the present economic climate. Or will it come in the UK, for example, as a result of sustained lobbying by the National Council for Hospice and Specialist Palliative Care Services and others to obtain a fairer proportion of the many millions of pounds spent annually on cancer research? But, however achieved, until more money becomes available, palliative care research is likely to be under-resourcedto the disadvantage of all those who will ultimately need such care; namely, most of us.
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